BLTEBelite Bio Inc American Depositary Shares

Belite Bio (BLTE) is back in focus after the FDA accepted its New Drug Application for tinlarebant with Priority Review, a key regulatory step that accompanies the company’s latest quarterly earnings report. See our latest analysis for Belite Bio. Belite Bio’s share price has been volatile around these updates, with a one day share price return down 7.07% but a 30 day share price return of 11.25% and a one year total shareholder return of 149.56%. This suggests momentum has been strong over a...

Belite Bio stock has delivered a very large 431.2% return over the past three years, while its valuation checks and current market multiples point to a less straightforward picture of how much is already priced in. Belite Bio has returned 431.2% over three years, which sets a high bar for any further upside to be justified by the fundamentals. Regulatory progress for tinlarebant, including the FDA Priority Review for Stargardt Disease Type 1, can support expectations for future cash...

Belite Bio Inc (BLTE) reports robust progress with FDA NDA acceptance and a $780 million cash runway, despite widening losses and delayed GA trial interim analysis.

Belite Bio (NASDAQ:BLTE) said the U.S. Food and Drug Administration has accepted its New Drug Application for tinlarebant, an investigational treatment for Stargardt disease, and granted the application priority review. The agency set a Prescription Drug User Fee Act action date of Feb. 12, 2027. C

Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.

Panelists at the H.C. Wainwright Sixth Annual Ophthalmology Virtual Conference said investigational therapies for inherited retinal disorders could begin to reshape treatment options for Stargardt disease and retinitis pigmentosa, two conditions with limited or no approved treatment choices today.